Retro Biosciences
Last verified 2026-05-07. JSON
The funding figures on this page are attributed, not sourced: a publisher is on record but no document URL is. How we mark provenance.
| Total raised | $1.2Battributed |
|---|---|
| Latest round | series-a, $1.0B, 2025-01-24attributed |
| Founded | 2021 |
| Headquarters | San Francisco, US |
| Industry | bio |
| Stage | series-a |
| Website | retro.bio |
Retro Biosciences develops therapeutics that extend healthy lifespan, with programs in autophagy, cellular reprogramming, and plasma fractions. The audience is patients with age-driven diseases and clinicians seeking interventions that target biological aging. Retro is funded in large part by Sam Altman's personal capital.
Funding rounds
| Date | Round | Amount | Lead |
|---|---|---|---|
| 2025-01-24 | series-a | $1.0B | undisclosed |
Detected tech stack
Vercel, Next.js, React
Provenance
| Fact | Status | Basis |
|---|---|---|
| Series A, $1.0B | attributed | techcrunch named as publisher. No document URL on file. |
| Total raised $1.2B | attributed | techcrunch named as publisher. No document URL on file. |
| Company existence | self-reported | retro.bio, read 2026-05-07 |
| Description | self-reported | retro.bio, read 2026-05-07 |
Nothing on this page is sourced yet. A sourced fact links to a document that states it.
Change history
No change recorded since records began on 2026-09-24.